Emerging antidyslipidemic drugs

Bibliography

• Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006;113:647-56
   PubMed Web of Science ®Google Scholar
• Johansen H, Nair C. The changing face of heart disease and stroke in Canada 2000. In: Wielgosz A, Arango M, Carew M, Ferguson M, Johansen H, Nair C, et al., editors. Health Outcomes. Ottawa, Canada: Heart and Stroke Foundation of Canada; 1999. p. 65-85
   Google Scholar
• Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-8
   PubMedGoogle Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090-100
   PubMed Web of Science ®Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8
   PubMed Web of Science ®Google Scholar
• Abbott RD, Wilson PW, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988;8:207-11
   PubMedGoogle Scholar
• Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41
   PubMedGoogle Scholar
• Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36:232-40
   PubMed Web of Science ®Google Scholar
• Hussain MM, Fatma S, Pan X, et al. Intestinal lipoprotein assembly. Curr Opin Lipidol 2005;16:281-5
   PubMed Web of Science ®Google Scholar
• Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001;12:151-7
   PubMed Web of Science ®Google Scholar
• Vance DE, Vance JE. Biochemistry of lipids, lipoproteins and membranes. 4th edition. Amsterdam: Elsevier Science; 2002
   Google Scholar
• Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97
   PubMed Web of Science ®Google Scholar
• Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
   PubMed Web of Science ®Google Scholar
• Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38-48
   PubMed Web of Science ®Google Scholar
• Pipeline insight: Antidyslipidemics – The power of two. Market Research.com, 2005. Available from: http://www.marketresearch.com/search/results.asp?sid=97553088-405814861-501265549&query= antidyslipidemic&vendorid=72&publisher=Datamonitor [Last accessed 26 February 2008]
   Google Scholar
• Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Superko HR, King S 3rd. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008;117:560-8; discussion 68
   PubMed Web of Science ®Google Scholar
• Mays ME, Dujovne CA. Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia? Curr Atheroscler Rep 2008;10:45-52
   PubMed Web of Science ®Google Scholar
• Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-82
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Ahn SC. Neuromuscular complications of statins. Phys Med Rehabil Clin North Am 2008;19:47-59
   PubMed Web of Science ®Google Scholar
• Sueta CA, Massing MW, Chowdhury M, et al. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail 2003;9:36-41
   PubMed Web of Science ®Google Scholar
• Hoeg JM. Pharmacologic and surgical treatment of dyslipidemic children and adolescents. Ann NY Acad Sci 1991;623:275-84
   PubMed Web of Science ®Google Scholar
• Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drugs 2001;1:141-6; discussion 47-8
   PubMedGoogle Scholar
• Leren TP, Hjermann I, Berg K, et al. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988;73:135-41
   PubMed Web of Science ®Google Scholar
• Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA 1987;257:33-8
   PubMed Web of Science ®Google Scholar
• Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53-8
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13
   PubMed Web of Science ®Google Scholar
• Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPAR-alpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 2007;48:2725-35
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
   PubMed Web of Science ®Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:27C-31C
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53
   PubMed Web of Science ®Google Scholar
• Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007;14:99-108
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15
   PubMed Web of Science ®Google Scholar
• McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-7
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008;62:88-96
   PubMed Web of Science ®Google Scholar
• Malik S, Kashyap ML. Niacin, lipids, and heart disease. Curr Cardiol Rep 2003;5:470-6
   PubMedGoogle Scholar
• Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
   PubMed Web of Science ®Google Scholar
• Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-74
   PubMed Web of Science ®Google Scholar
• Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303:364-9
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81
   PubMed Web of Science ®Google Scholar
• Charlton-Menys V, Durrington PN. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential. Drugs 2007;67:11-6
   PubMed Web of Science ®Google Scholar
• Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin Investig Drugs 2006;15:1337-51
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004;110:3372-7
   PubMed Web of Science ®Google Scholar
• Rudel LL, Lee RG, Cockman TL. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol 2001;12:121-7
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997;1345:136-50
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992;258:999-1001
   PubMed Web of Science ®Google Scholar
• Liao W, Hui TY, Young SG, et al. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 2003;44:978-85
   PubMed Web of Science ®Google Scholar
• Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-4
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74
   PubMed Web of Science ®Google Scholar
• Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985;58:175-86
   PubMed Web of Science ®Google Scholar
• Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8
   PubMed Web of Science ®Google Scholar
• Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007;48:1263-72
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257-60
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Segrest JP, Li L, Anantharamaiah GM, et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000;11:105-15
   PubMed Web of Science ®Google Scholar
• Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94
   PubMed Web of Science ®Google Scholar
• Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-11
   PubMed Web of Science ®Google Scholar
• Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001;42:545-52
   PubMed Web of Science ®Google Scholar
• Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an ApoA-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290-2
   PubMed Web of Science ®Google Scholar
• Ou J, Wang J, Xu H, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005;97:1190-7
   PubMed Web of Science ®Google Scholar
• Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003;107:2337-41
   PubMed Web of Science ®Google Scholar
• Li X, Chyu KY, Faria Neto JR, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004;110:1701-5
   PubMed Web of Science ®Google Scholar
• Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Goff DC Jr, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
   PubMed Web of Science ®Google Scholar
• Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-8
   PubMed Web of Science ®Google Scholar
• Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007;18:304-9
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008
   Google Scholar
• Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4
   PubMed Web of Science ®Google Scholar
• Akdim F, Harchaoui KE, Stroes ES, et al. Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidol 2007;2:387-93
   Web of Science ®Google Scholar
• Kramer W, Corsiero D, Girbig F, et al. Rabbit small intestine does not contain an annexin II/caveolin 1 complex as a target for 2-azetidinone cholesterol absorption inhibitors. Biochim Biophys Acta 2006;1758:45-54
   PubMed Web of Science ®Google Scholar
• A study evaluating the safety and efficacy of AVE5530 (4 weeks) in patients with mild to moderate hypercholesterolemia, NCT00440154, 2008. Available from: http://www.clinicaltrials.gov [Last accessed 16 March 2008]
   Google Scholar
• Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56
   PubMed Web of Science ®Google Scholar
• Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005;5:30
   PubMedGoogle Scholar
• Homma Y, Kobayashi T, Yamaguchi H, et al. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997;129:241-8
   Google Scholar
• Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis 2002;164:381-2
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-8
   PubMed Web of Science ®Google Scholar
• Shneider BL. Intestinal bile acid transport: biology, physiology, and pathophysiology. J Pediatr Gastroenterol Nutr 2001;32:407-17
   PubMed Web of Science ®Google Scholar
• Zhang EY, Phelps MA, Cheng C, et al. Modeling of active transport systems. Adv Drug Deliv Rev 2002;54:329-54
   PubMed Web of Science ®Google Scholar
• Kitayama K, Nakai D, Kono K, et al. Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol 2006;539:89-98
   PubMed Web of Science ®Google Scholar
• Wasan KM, Najafi S, Wong J, et al. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water-soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci 2001;4:228-34
   PubMed Web of Science ®Google Scholar
• Looije NA, Risovic V, Stewart DJ, et al. Disodium ascorbyl phytostanyl phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci 2005;8:400-8
   PubMed Web of Science ®Google Scholar
• Lukic T, Wasan KM, Zamfir D, et al. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism 2003;52:425-31
   PubMed Web of Science ®Google Scholar
• Ramaswamy M, Yau E, Wasan KM, et al. Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharm Pharm Sci 2002;5:29-38
   PubMed Web of Science ®Google Scholar
• Wasan KM, Yau E, Boulanger KD, et al. Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells. AAPS PharmSci 2003;5:E6
   PubMedGoogle Scholar
• Forbes Medi-Tech, Inc., FM-VP4: a new class of cholesterol lowering drugs, 2008. Available from: http://www. forbesmedi.com/s/FM-VP4.asp [Last accessed 6 February 2008]
   Google Scholar
• Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-57
   PubMed Web of Science ®Google Scholar
• Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. ClinicalTrials.gov, 2007. Available from: http://www.clinicaltrials.gov/ct/show/NCT00461630?order=6 [Last accessed 15 February 2008]
   Google Scholar
• Stamler CJ, Breznan D, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport in vivo. J Lipid Res 2000;41:1214-21
   PubMed Web of Science ®Google Scholar
• Burgess JW, Boucher J, Neville TA, et al. Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res 2003;44:1355-63
   PubMed Web of Science ®Google Scholar
• Burgess JW, Neville TA, Rouillard P, et al. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 2005;46:350-5
   PubMed Web of Science ®Google Scholar
• Pandey NR, Renwick J, Misquith A, et al. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion. Biochemistry 2008;47:1579-87
   PubMed Web of Science ®Google Scholar
• Liponex, Inc. CRD5 Science. Available from: http://www.liponex.ca/science/crd5.html [Last accessed 6 February 2008]
   Google Scholar
• Liponex updates CRD5 status and corporate strategy (News: December 13, 2007). Available from: http://www.liponex.ca/ut/pdf/12.13.07%20Liponex%20Updates%20CRD5%20Status.pdf [Last accessed 6 February 2008]
   Google Scholar
• Gillard BK, Courtney HS, Massey JB, et al. Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. Biochemistry 2007;46:12968-78
   PubMed Web of Science ®Google Scholar
• Alnylam presents first ever non-human primate data with an RNAi therapeutic targeting PCSK9 showing significant and durable reductions in LDL cholesterol levels, 2007. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle2&ID=1059699&highlight= [Last accessed 26 February 2008]
   Google Scholar
• Bristol-Myers Squibb enters cardiovascular disease collaboration with Isis Pharmaceuticals, 2007. Available from: http://ir.isispharm.com/releasedetail.cfm?ReleaseID=241674 [Last accessed 28 February 2008]
   Google Scholar
• Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007;18:397-400
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35
   PubMed Web of Science ®Google Scholar
• Isis reports positive results of phase 2 study of ISIS 301012 in heterozygous FH patients, 2007. Available from: http://ir.isispharm.com/releasedetail.cfm?ReleaseID=267339 [Last accessed 3 March 2008]
   Google Scholar
• Isis Pharmaceuticals updates its positive phase 2 data for ISIS 301012 in familial hypercholesterolemia patients, 2007. Available from: http://ir.isispharm.com/releasedetail.cfm?ReleaseID=244309 [Last accessed 28 February 2008]
   Google Scholar
• Isis reports new data for mipomersen in routine high cholesterol patients and provides cumulative safety summary, 2007. Available from: http://ir.isispharm.com/releasedetail.cfm?ReleaseID=275455 [Last accessed 28 February 2008]
   Google Scholar